XNAS
ABSI
Market cap362mUSD
Jun 13, Last price
2.78USD
1D
-5.65%
1Q
-9.55%
IPO
-87.59%
Name
Absci Corp
Chart & Performance
P/E
—
P/S
78.21
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.63%
Rev. gr., 5y
17.09%
Revenues
5m
-20.71%
Net income
-103m
L-6.75%
CFO
-72m
L+12.01%
Earnings
Aug 12, 2025
Profile
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 4,534 -20.71% | 5,718 -0.50% | 5,747 20.18% | |||
Cost of revenue | 63,859 | 95,634 | 71,945 | |||
Unusual Expense (Income) | ||||||
NOPBT | (59,325) | (89,916) | (66,198) | |||
NOPBT Margin | ||||||
Operating Taxes | 70 | 100 | (461) | |||
Tax Rate | ||||||
NOPAT | (59,395) | (90,016) | (65,737) | |||
Net income | (103,106) -6.75% | (110,566) 5.40% | (104,904) 3.91% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 86,557 | 862 | 656 | |||
BB yield | -29.97% | -0.22% | -0.34% | |||
| Debt | ||||||
Debt current | 1,686 | 5,578 | 6,932 | |||
Long-term debt | 13,277 | 18,418 | 28,104 | |||
Deferred revenue | 966 | |||||
Other long-term liabilities | 33 | 35 | ||||
Net debt | (97,462) | (73,663) | (131,259) | |||
| Cash flow | ||||||
Cash from operating activities | (72,402) | (64,636) | (81,339) | |||
CAPEX | (404) | (860) | (16,175) | |||
Cash from investing activities | (41,577) | 81,944 | (126,982) | |||
Cash from financing activities | 82,526 | (4,483) | 5,237 | |||
FCF | (46,712) | (77,792) | (65,127) | |||
| Balance | ||||||
Cash | 112,425 | 97,659 | 164,431 | |||
Long term investments | 1,864 | |||||
Excess cash | 112,198 | 97,373 | 166,008 | |||
Stockholders' equity | (509,593) | (406,523) | (296,040) | |||
Invested Capital | 696,231 | 599,655 | 593,472 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 110,240 | 92,028 | 90,846 | |||
Price | 2.62 -37.62% | 4.20 100.00% | 2.10 -74.39% | |||
Market cap | 288,828 -25.27% | 386,518 102.60% | 190,776 -74.89% | |||
EV | 191,366 | 312,855 | 59,517 | |||
EBITDA | (45,936) | (75,917) | (53,161) | |||
EV/EBITDA | ||||||
Interest | 565 | 1,010 | 972 | |||
Interest/NOPBT | ||||||